Basic Information
FERRIPROX 100MG/ML ORAL SOLUTION
SOLUTION
Regulatory Information
SIN13668P
June 26, 2009
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 4, 2025
XV03AC02
Company Information
Active Ingredients
Strength: 100.00g/l
Detailed Information
Contraindications
**4.3 Contraindications** - Hypersensitivity to the active substance or to any of the excipients. - History of recurrent episodes of neutropenia. - History of agranulocytosis. - Pregnancy or breast-feeding (see section 4.6 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). - Due to the unknown mechanism of deferiprone-induced neutropenia, patients must not take medicinal products known to be associated with neutropenia or those that can cause agranulocytosis (see section 4.5 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Ferriprox is indicated for the treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate.